Eritrea vs South Africa: Statin use vs. average non-HDL cholesterol levels
Eritrea
3
in 2018
South Africa
3
in 2018
Eritrea rank
146th
South Africa rank
146th
Statin use vs. average non-HDL cholesterol levels over time
- Eritrea
- South Africa
How they compare
Eritrea currently reports 3 against 3 in South Africa, a difference of 0.
Across all 39 years both countries report, South Africa has been ahead every year.
Eritrea ranks 146th and South Africa ranks 146th of 191 countries.
South Africa has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Eritrea | South Africa | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 2.49 | 3.2 | 0.71 | South Africa |
| 1990s | 2.65 | 3.2 | 0.55 | South Africa |
| 2000s | 2.82 | 3.2 | 0.38 | South Africa |
| 2010s | 2.97 | 3.11 | 0.1444 | South Africa |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Eritrea or South Africa?
- Eritrea, at 3 against 3 in South Africa as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Eritrea and South Africa?
- 0, with Eritrea ahead.
- How many years of comparable data are there for Eritrea and South Africa?
- 39 years are reported by both, from 1980 to 2018.
- How do Eritrea and South Africa rank globally for statin use vs. average non-hdl cholesterol levels?
- Eritrea ranks 146th and South Africa ranks 146th of 191 countries.
- Where does this data come from?
- World Health Organization – Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.